Development of Drug-Resistant Klebsiella pneumoniae Vaccine via Novel Vesicle Production Technology.
Weiran LiYing HuQishu ZhangLiangqun HuaZhongqian YangZhaoling RenXiao ZhengWeiwei HuangYanbing MaPublished in: ACS applied materials & interfaces (2021)
Drug resistance of Klebsiella pneumoniae severely threatens human health. Overcoming the mechanisms of K. pneumoniae resistance to develop novel vaccines against drug-resistant K. pneumoniae is highly desired. Here, we report a technology platform that uses high pressure to drive drug-resistant K. pneumoniae to pass through a gap, inducing the formation of stable artificial bacterial biomimetic vesicles (BBVs). These BBVs had little to no bacterial intracellular protein or nucleic acid and had high yields. BBVs were efficiently taken up by dendritic cells to stimulate their maturation. BBVs as K. pneumoniae vaccines had the dual functions of inducing bacteria-specific humoral and cellular immune responses to increase animals' survival rate and reduce pulmonary inflammation and bacterial loads. We believe that BBVs are new-generation technology for bacterial vesicle preparation. Establishment of this BBV vaccine platform can maximally expand preparation technology for vaccines against drug-resistant K. pneumoniae.
Keyphrases
- drug resistant
- multidrug resistant
- klebsiella pneumoniae
- immune response
- acinetobacter baumannii
- dendritic cells
- human health
- nucleic acid
- escherichia coli
- respiratory tract
- risk assessment
- high throughput
- oxidative stress
- pulmonary hypertension
- regulatory t cells
- climate change
- reactive oxygen species
- protein protein
- small molecule
- high resolution
- single cell
- binding protein
- tandem mass spectrometry
- free survival
- solid phase extraction